regenics semaglutide (@regenicsla) Semaglutide GLP-1 Receptor Agonist Research
Description
On August 1, 2024, North Carolina Medicaid launched coverage for glucagon-like peptide 1 (GLP-1s) drugs for weight loss despite the State Health Plan (SHP) ending coverage on April 1, 2024
Emerging research is demonstrating that taking Ozempic may cause blindness related to NAION in rare instances
Please note that the pricing above is solely for the medication and does not include doctors' visits, labs, or our membership costs
The total hypoglycemic event rate is higher with oral semaglutide 14 mg based on PIONEER 3, so the assumption that the metformin + oral semaglutide 14 mg + insulin glargine combination is associated with the same hypoglycemic event rate as metformin + sitagliptin 100 mg + insulin glargine could skew the results in favor of oral semaglutide 14 mg
This includes everything involved in treatment support, follow-up visits, medication, and shipping
GLP-1 drugs havent disappeared
